BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$403.60−9.66 (-2.34%)
Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –
BeOne Medicines revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
BeOne Medicines's revenue for the twelve months ending Jun 30, 2026 was $6.13B, up 34.3% year over year. For fiscal 2025 it was $5.34B, up 40.2% from the year before. Over ten years it grew 89.8% a year on average. The highest annual figure on record is $5.34B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.34B | +40.2% |
| FY2024 | Dec 31, 2024 | $3.81B | +55.0% |
| FY2023 | Dec 31, 2023 | $2.46B | +73.7% |
| FY2022 | Dec 31, 2022 | $1.42B | +20.4% |
| FY2021 | Dec 31, 2021 | $1.18B | +280.8% |
| FY2020 | Dec 31, 2020 | $308.87M | -27.9% |
| FY2019 | Dec 31, 2019 | $428.21M | +116.0% |
| FY2018 | Dec 31, 2018 | $198.22M | -16.8% |
| FY2017 | Dec 31, 2017 | $238.39M | +22179.2% |
| FY2016 | Dec 31, 2016 | $1.07M | -87.9% |
| FY2015 | Dec 31, 2015 | $8.82M | -32.4% |
| FY2014 | Dec 31, 2014 | $13.04M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.71B | +29.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.51B | +35.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.50B | +32.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.41B | +41.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.32B | +41.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.12B | +48.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.13B | +77.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.00B | +28.2% |
| Q2 FY2024 | Jun 30, 2024 | $929.17M | +56.1% |
| Q1 FY2024 | Mar 31, 2024 | $751.65M | +67.9% |
| Q4 FY2023 | Dec 31, 2023 | $634.41M | +66.9% |
| Q3 FY2023 | Sep 30, 2023 | $781.31M | +101.6% |
| Q2 FY2023 | Jun 30, 2023 | $595.26M | +74.3% |
| Q1 FY2023 | Mar 31, 2023 | $447.80M | +46.0% |
| Q4 FY2022 | Dec 31, 2022 | $380.10M | +77.6% |
| Q3 FY2022 | Sep 30, 2022 | $387.63M | +87.8% |
| Q2 FY2022 | Jun 30, 2022 | $341.57M | +127.7% |
| Q1 FY2022 | Mar 31, 2022 | $306.63M | -49.4% |
| Q4 FY2021 | Dec 31, 2021 | $213.98M | +113.8% |
| Q3 FY2021 | Sep 30, 2021 | $206.44M | +126.7% |
| Q2 FY2021 | Jun 30, 2021 | $149.99M | +128.5% |
| Q1 FY2021 | Mar 31, 2021 | $605.87M | +1063.8% |
| Q4 FY2020 | Dec 31, 2020 | $100.10M | +75.9% |
| Q3 FY2020 | Sep 30, 2020 | $91.08M | +81.6% |
| Q2 FY2020 | Jun 30, 2020 | $65.64M | -73.0% |
| Q1 FY2020 | Mar 31, 2020 | $52.06M | -33.1% |
| Q4 FY2019 | Dec 31, 2019 | $56.89M | -3.0% |
| Q3 FY2019 | Sep 30, 2019 | $50.14M | -7.5% |
| Q2 FY2019 | Jun 30, 2019 | $243.35M | +360.8% |
| Q1 FY2019 | Mar 31, 2019 | $77.83M | +139.2% |
| Q4 FY2018 | Dec 31, 2018 | $58.67M | +222.8% |
| Q3 FY2018 | Sep 30, 2018 | $54.20M | -75.4% |
| Q2 FY2018 | Jun 30, 2018 | $52.80M | – |
| Q1 FY2018 | Mar 31, 2018 | $32.54M | – |
| Q4 FY2017 | Dec 31, 2017 | $18.17M | – |
| Q3 FY2017 | Sep 30, 2017 | $220.21M | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?